Long-term clinical benefits of Sofosbuvir-based direct antiviral regimens for patients with chronic hepatitis C in Central and West Africa.

Liver International : Official Journal of the International Association for the Study of the Liver
Mael BaudoinSylvie Boyer

Abstract

In Sub-Saharan Africa, chronic hepatitis C (CHC) is a major public health issue. We estimated the long-term clinical benefits of treating CHC with sofosbuvir-based regimens in Cameroon, Côte d'Ivoire and Senegal using Markov model combining data from the literature with estimates of direct-acting antiviral (DAAs) effectiveness in West and Central Africa. Disease progression was simulated with and without treatment in fictive cohorts of patients "diagnosed" with CHC in Cameroon (n = 3224), Côte d'Ivoire (n = 9748) and Senegal (n = 6358). Lifetime treatment benefits were assessed using (a) life-years saved (LYS); (b) life-years (LY) avoided in compensated cirrhosis (CC), decompensated cirrhosis (DC) and hepatocellular carcinoma; and (c) comparison of the proportions of patients at each disease stage with and without treatment. Probabilistic and determinist sensitivity analyses were performed to address uncertainty. Sofosbuvir-based treatment would save [mean, 95% confidence intervals] 3.3 (2.5; 5.7) LY per patient in Cameroon, 2.7 (2.1; 4.8) in Côte d'Ivoire and 3.6 (2.8; 6.3) in Senegal. With treatment, approximately 6% (1%) of the patients still alive in each of the study countries would be in the CC (DC) health state 11 (15) y...Continue Reading

References

Jun 20, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hla-Hla TheinMurray D Krahn
Apr 27, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jules L DienstagUNKNOWN HALT-C Trial Group
Sep 20, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Andrew H BriggsUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Mar 21, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Samer S El-KamaryGamal Esmat
Apr 24, 2013·The New England Journal of Medicine·Ira M JacobsonUNKNOWN FUSION Study
Apr 24, 2013·The New England Journal of Medicine·Eric LawitzEdward J Gane
Feb 11, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dorothée ObachYazdan Yazdanpanah
Apr 12, 2014·The New England Journal of Medicine·Kris V KowdleyUNKNOWN ION-3 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
May 6, 2014·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN VALENCE Investigators
Dec 3, 2014·Journal of Hepatology·Rachel H Westbrook, Geoffrey Dusheiko
Jan 21, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Bryony SimmonsGraham S Cooke
Jun 23, 2016·Applied Health Economics and Health Policy·Miriam LuhnenGloria Hanke
Sep 14, 2016·Journal of Hepatology·Stanislas PolUNKNOWN ANRS/AFEF HEPATHER study group
Oct 25, 2016·Journal of Hepatology·Maud Lemoine, Mark R Thursz
Apr 14, 2017·The Lancet. Gastroenterology & Hepatology·Ju Dong YangUNKNOWN Africa Network for Gastrointestinal and Liver Diseases
Apr 14, 2017·The Lancet. Gastroenterology & Hepatology·UNKNOWN Polaris Observatory HCV Collaborators
May 23, 2017·Journal of the International AIDS Society·Léa DuchesneKarine Lacombe
Apr 11, 2018·Journal of the International AIDS Society·Anders BoydKarine Lacombe
Dec 16, 2018·The Lancet. Gastroenterology & Hepatology·Neil GuptaPhilip M Grant

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.